Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate ...

Pipeline expansion into neoantigens with multiple KRAS mutations as the first targetsAcquired exclusive, worldwide rights to a CD40L-CD28 costimulatory switch proteinData from MDG1015 and multiple TCRs combined with PD1-41BB costimulatory

Related Keywords

Japan ,United States ,China ,American ,Pamela Keck ,Kirsty Crame ,Planegg Martinsried ,Research Development ,Head Of Clinical Research Development ,American Academy Of Cancer Research ,National Cancer Institute ,Development Agreement ,Japan Patent Office ,American Academy ,Cancer Research ,Immuno Oncology Summit Europe ,Prime Standard ,Chief Executive Officer ,Executive Management Board ,Cooperative Research ,Investor Relations ,Corporate Communications ,Clinical Research ,Development Highlights ,Business ,